<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Dr. Martens Plc — News on 6ix</title>
    <link>https://6ix.com/company/dr-martens-plc</link>
    <description>Latest news and press releases for Dr. Martens Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 08 Apr 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/dr-martens-plc" rel="self" type="application/rss+xml" />
    <item>
      <title>Appointment of Market General Managers</title>
      <link>https://6ix.com/company/dr-martens-plc/news/appointment-of-market-general-managers</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/appointment-of-market-general-managers</guid>
      <pubDate>Wed, 08 Apr 2026 06:00:00 GMT</pubDate>
      <description>Dr. Martens PLC is implementing a new market general manager structure and has created an Executive Team to accelerate strategic delivery, with the six key markets accounting for over 80% of global revenues now having dedicated leaders. The newly formed Executive Team, led by the CEO, includes the CFO, Chief Brand Officer, interim Chief Operating Officer, Chief Commercial Officer, President of Americas, Chief People Officer, and Chief Legal Officer. This organizational change aims to embed a con</description>
    </item>
    <item>
      <title>Total Voting Rights</title>
      <link>https://6ix.com/company/dr-martens-plc/news/total-voting-rights-303</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/total-voting-rights-303</guid>
      <pubDate>Fri, 27 Feb 2026 11:04:00 GMT</pubDate>
      <description>Dr. Martens plc has announced its total voting rights as of February 27, 2026, stating that its issued ordinary share capital consists of 967,343,738 ordinary shares, each with one voting right, and that no shares are held in Treasury. This figure of 967,343,738 represents the total number of shares with voting rights and serves as the denominator for shareholders calculating their notification obligations under the FCA&apos;s Disclosure Guidance and Transparency Rules.
                Disclaimer*</description>
    </item>
    <item>
      <title>EBT Share Purchase</title>
      <link>https://6ix.com/company/dr-martens-plc/news/ebt-share-purchase</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/ebt-share-purchase</guid>
      <pubDate>Thu, 29 Jan 2026 07:00:00 GMT</pubDate>
      <description>Dr. Martens plc has announced that it has recommended the Employee Benefit Trust purchase up to 10 million ordinary shares in the market, with these shares to be held unallocated for future employee share plan awards.
                Disclaimer*</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/dr-martens-plc/news/holdings-in-company-126</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/holdings-in-company-126</guid>
      <pubDate>Tue, 27 Jan 2026 07:00:00 GMT</pubDate>
      <description>FMR LLC has increased its stake in Dr. Martens PLC, crossing a notification threshold on January 22, 2026. The firm now holds 8.3385% of the voting rights, representing 80,657,648 shares, up from a previous holding of 5.91%. This acquisition was made by Fidelity Management &amp; Research Company LLC, a controlled undertaking of FMR LLC.
                Disclaimer*</description>
    </item>
    <item>
      <title>Q3 FY26 Trading Statement</title>
      <link>https://6ix.com/company/dr-martens-plc/news/q3-fy26-trading-statement-1</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/q3-fy26-trading-statement-1</guid>
      <pubDate>Tue, 27 Jan 2026 07:00:00 GMT</pubDate>
      <description>Dr. Martens plc reported a Q3 Group revenue decrease of 2.7% on a constant currency basis to £253 million, with year-to-date revenue down 0.7% to £580 million, primarily due to a disciplined approach to promotions and reduced clearance activity impacting Direct to Consumer (DTC) revenue, which fell 6.5% in Q3. However, wholesale revenue showed strength, increasing 9.5% in Q3 and 4.2% year-to-date on a constant currency basis, with good growth across all regions, particularly in the Americas wher</description>
    </item>
    <item>
      <title>Director/PDMR Shareholding</title>
      <link>https://6ix.com/company/dr-martens-plc/news/directorpdmr-shareholding-134</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/directorpdmr-shareholding-134</guid>
      <pubDate>Thu, 15 Jan 2026 09:24:00 GMT</pubDate>
      <description>Dr. Martens plc announced that on January 13, 2026, two directors, Ije Nwokorie and Giles Wilson, acquired 192 ordinary shares each at a price of 77.894 pence per share through the Company&apos;s Share Incentive Plan, and were also awarded an equal number of matching shares at no cost. This transaction, involving a total of 384 partnership shares and 384 matching shares, was conducted on the London Stock Exchange and outside of a trading venue.
                Disclaimer*</description>
    </item>
    <item>
      <title>Block listing Interim Review</title>
      <link>https://6ix.com/company/dr-martens-plc/news/block-listing-interim-review-63</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/block-listing-interim-review-63</guid>
      <pubDate>Mon, 01 Dec 2025 12:35:00 GMT</pubDate>
      <description>Dr. Martens plc has reported its six-month block listing return for employee share plans, showing a decrease in unallotted securities. The company began the period from June 1, 2025, to November 30, 2025, with 14,601,047 shares available. During this period, 1,852,112 shares were issued or allotted under the schemes, resulting in a remaining balance of 12,748,935 unallotted shares at the end of the reporting period.
                Disclaimer*</description>
    </item>
    <item>
      <title>H1 FY26 Results</title>
      <link>https://6ix.com/company/dr-martens-plc/news/h1-fy26-results</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/h1-fy26-results</guid>
      <pubDate>Thu, 20 Nov 2025 07:00:00 GMT</pubDate>
      <description>Dr. Martens plc reported a first-half revenue of £322.0 million, a slight decrease of 0.8% on a reported basis but up 0.8% in constant currency, with full-price direct-to-consumer revenue increasing by 6%. The company saw a significant improvement in adjusted profit before tax, narrowing the loss to £9.2 million from £16.6 million in the prior year, and reported a gross margin of 65.3%. Net bank debt decreased to £302.3 million, and an interim dividend of 0.85p per share was declared. The compan</description>
    </item>
    <item>
      <title>Gen Phoenix and Dr. Martens Celebrate Four Seasons of Waste Reduction with the Launch of the Solar Flare Collection</title>
      <link>https://6ix.com/company/dr-martens-plc/news/gen-phoenix-and-dr-martens-celebrate-four-seasons-of-waste-reduction-with-the-launch-of-the-solar-flare-collection</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/gen-phoenix-and-dr-martens-celebrate-four-seasons-of-waste-reduction-with-the-launch-of-the-solar-flare-collection</guid>
      <pubDate>Wed, 12 Nov 2025 14:00:00 GMT</pubDate>
      <description>PETERBOROUGH, England, November 12, 2025--Material innovator Gen Phoenix and heritage footwear brand Dr. Martens are marking a major milestone in sustainable design: four consecutive seasons of partnership. In celebration of this continued collaboration, which began with the launch of the Genix Nappa collection in 2024, and just in time for the holidays, Dr. Martens is introducing the Solar Flare collection made with Genix Nappa to underscore both brands’ shared commitment to long-term impact ov</description>
    </item>
    <item>
      <title>Appointment of joint corporate broker</title>
      <link>https://6ix.com/company/dr-martens-plc/news/appointment-of-joint-corporate-broker-19</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/appointment-of-joint-corporate-broker-19</guid>
      <pubDate>Fri, 10 Oct 2025 06:00:00 GMT</pubDate>
      <description>Dr. Martens PLC announced the appointment of Berenberg as a joint corporate broker, effective immediately, to work alongside Investec and Goldman Sachs. This addition expands the company&apos;s brokerage team.

                Disclaimer*</description>
    </item>
    <item>
      <title>UAE distribution partnership and LATAM expansion</title>
      <link>https://6ix.com/company/dr-martens-plc/news/uae-distribution-partnership-and-latam-expansion</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/uae-distribution-partnership-and-latam-expansion</guid>
      <pubDate>Thu, 02 Oct 2025 06:00:00 GMT</pubDate>
      <description>Dr. Martens announced a new distribution partnership with Beside Group, marking the brand&apos;s entry into the UAE. This partnership will initially focus on wholesale, with plans for mono-branded store openings in the future. Additionally, Dr. Martens has partnered with Crosby in Latin America and opened its second store in the region, located in Santiago, Chile, this week. The first store opened in Argentina in August. These partnerships align with Dr. Martens&apos; strategy of entering new growth marke</description>
    </item>
    <item>
      <title>Director/PCA Shareholding</title>
      <link>https://6ix.com/company/dr-martens-plc/news/directorpca-shareholding</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/directorpca-shareholding</guid>
      <pubDate>Tue, 02 Sep 2025 08:30:00 GMT</pubDate>
      <description>On September 1, 2025, Dr. Martens plc announced that Giles Wilson, Chief Financial Officer, purchased 105,838 shares at £0.91377 per share, after selling 105,785 shares at £0.8965 per share. Concurrently, Katie Wilson, a person closely associated with Giles Wilson, purchased 30,019 shares at £0.911447 per share, subsequent to selling 30,000 shares at £0.910823 per share. These transactions involved moving holdings into ISAs. Following these transactions, Giles Wilson&apos;s total beneficial interest </description>
    </item>
    <item>
      <title>Result of 2025 AGM</title>
      <link>https://6ix.com/company/dr-martens-plc/news/result-of-2025-agm-2</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/result-of-2025-agm-2</guid>
      <pubDate>Thu, 10 Jul 2025 09:58:00 GMT</pubDate>
      <description>Result of 2025 AGM.</description>
    </item>
    <item>
      <title>AGM Trading Update</title>
      <link>https://6ix.com/company/dr-martens-plc/news/agm-trading-update-14</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/agm-trading-update-14</guid>
      <pubDate>Thu, 10 Jul 2025 06:00:00 GMT</pubDate>
      <description>AGM Trading Update.</description>
    </item>
    <item>
      <title>Annual Financial Report</title>
      <link>https://6ix.com/company/dr-martens-plc/news/annual-financial-report-30</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/annual-financial-report-30</guid>
      <pubDate>Tue, 17 Jun 2025 08:00:00 GMT</pubDate>
      <description>Annual Financial Report.</description>
    </item>
    <item>
      <title>Final Results</title>
      <link>https://6ix.com/company/dr-martens-plc/news/final-results-40</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/final-results-40</guid>
      <pubDate>Thu, 05 Jun 2025 06:00:00 GMT</pubDate>
      <description>Final Results.</description>
    </item>
    <item>
      <title>Director Declaration</title>
      <link>https://6ix.com/company/dr-martens-plc/news/director-declaration-65</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/director-declaration-65</guid>
      <pubDate>Tue, 27 May 2025 07:45:00 GMT</pubDate>
      <description>Director Declaration.</description>
    </item>
    <item>
      <title>Appointment of Non-Executive Directors</title>
      <link>https://6ix.com/company/dr-martens-plc/news/appointment-of-non-executive-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/appointment-of-non-executive-directors-1</guid>
      <pubDate>Wed, 12 Feb 2025 07:00:00 GMT</pubDate>
      <description>Appointment of Non-Executive Directors.</description>
    </item>
    <item>
      <title>Q3 FY25 Trading Statement</title>
      <link>https://6ix.com/company/dr-martens-plc/news/q3-fy25-trading-statement</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/q3-fy25-trading-statement</guid>
      <pubDate>Mon, 27 Jan 2025 07:00:00 GMT</pubDate>
      <description>Q3 FY25 Trading Statement.</description>
    </item>
    <item>
      <title>Block Listing Application</title>
      <link>https://6ix.com/company/dr-martens-plc/news/block-listing-application-14</link>
      <guid isPermaLink="true">https://6ix.com/company/dr-martens-plc/news/block-listing-application-14</guid>
      <pubDate>Thu, 12 Dec 2024 07:00:00 GMT</pubDate>
      <description>Block Listing Application.</description>
    </item>
  </channel>
</rss>